Cantor Fitzgerald restated their buy rating on shares of Abeona Therapeutics (NASDAQ:ABEO) in a research note issued to investors on Tuesday, AnalystRatings.com reports. The firm currently has a $29.00 price target on the biopharmaceutical company’s stock.

“: We are reiterating our OW rating and $29 12-month price target on Abeona following 1Q19 earnings. Abeona announced the CMC work for the Phase 3 VITAL study in EB-101 for the treatment of recessive dystrophic epidermolysis bullosa (RDEB) has been completed. The trial could initiate in mid-2019, following the completion of the last checkbox regarding an ongoing FDA review. While specific timeline guidance has not been provided, pre-screening has begun, which could support a more rapid enrollment. Additionally, the company expects to announce interim data from the Sanfilippo Phase 1/2 studies.”,” the firm’s analyst commented.

ABEO has been the topic of a number of other reports. ValuEngine raised shares of Abeona Therapeutics from a sell rating to a hold rating in a research report on Tuesday, March 5th. BidaskClub raised shares of Abeona Therapeutics from a strong sell rating to a sell rating in a research report on Thursday, May 9th. Zacks Investment Research raised shares of Abeona Therapeutics from a sell rating to a hold rating in a research report on Wednesday, March 20th. HC Wainwright reissued a buy rating on shares of Abeona Therapeutics in a research report on Monday, May 6th. Finally, Maxim Group reissued a buy rating on shares of Abeona Therapeutics in a research report on Wednesday, May 1st. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and eight have issued a buy rating to the stock. Abeona Therapeutics currently has an average rating of Buy and a consensus target price of $26.00.

Abeona Therapeutics stock opened at $7.29 on Tuesday. The company has a market cap of $346.59 million, a price-to-earnings ratio of -6.13 and a beta of 1.92. Abeona Therapeutics has a 52-week low of $6.26 and a 52-week high of $21.45. The company has a current ratio of 3.35, a quick ratio of 4.37 and a debt-to-equity ratio of 0.06.

Abeona Therapeutics (NASDAQ:ABEO) last released its earnings results on Monday, March 18th. The biopharmaceutical company reported ($0.36) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.42) by $0.06. The company had revenue of $0.50 million for the quarter, compared to analyst estimates of $1.66 million. Abeona Therapeutics had a negative net margin of 960.91% and a negative return on equity of 45.58%. Equities analysts expect that Abeona Therapeutics will post -1.47 earnings per share for the current fiscal year.

In related news, Director Stephen B. Howell bought 4,000 shares of the company’s stock in a transaction that occurred on Monday, April 8th. The shares were purchased at an average cost of $7.77 per share, with a total value of $31,080.00. Following the transaction, the director now directly owns 6,000 shares of the company’s stock, valued at approximately $46,620. The purchase was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, Director Stefano Buono bought 70,000 shares of the company’s stock in a transaction that occurred on Thursday, April 11th. The stock was bought at an average cost of $7.80 per share, for a total transaction of $546,000.00. Following the completion of the transaction, the director now directly owns 20,980 shares in the company, valued at $163,644. The disclosure for this purchase can be found here. Corporate insiders own 33.60% of the company’s stock.

A number of institutional investors have recently modified their holdings of the business. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. grew its position in Abeona Therapeutics by 7.1% during the 1st quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 19,523 shares of the biopharmaceutical company’s stock worth $144,000 after purchasing an additional 1,286 shares during the last quarter. The Manufacturers Life Insurance Company lifted its stake in shares of Abeona Therapeutics by 18.2% in the 1st quarter. The Manufacturers Life Insurance Company now owns 12,589 shares of the biopharmaceutical company’s stock worth $93,000 after acquiring an additional 1,935 shares during the period. SG Americas Securities LLC lifted its stake in shares of Abeona Therapeutics by 23.7% in the 4th quarter. SG Americas Securities LLC now owns 22,720 shares of the biopharmaceutical company’s stock worth $162,000 after acquiring an additional 4,351 shares during the period. Alps Advisors Inc. lifted its stake in shares of Abeona Therapeutics by 4.5% in the 1st quarter. Alps Advisors Inc. now owns 115,800 shares of the biopharmaceutical company’s stock worth $852,000 after acquiring an additional 5,002 shares during the period. Finally, BNP Paribas Arbitrage SA lifted its stake in shares of Abeona Therapeutics by 21,590.0% in the 1st quarter. BNP Paribas Arbitrage SA now owns 6,507 shares of the biopharmaceutical company’s stock worth $48,000 after acquiring an additional 6,477 shares during the period. 67.53% of the stock is currently owned by institutional investors.

About Abeona Therapeutics

Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.

Featured Article: What Does a Sell-Side Analyst Rating Mean?

Analyst Recommendations for Abeona Therapeutics (NASDAQ:ABEO)

Receive News & Ratings for Abeona Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abeona Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.